ALZHEIMERSDRUG

Discovery of drugs for the treatment and prevention of Alzheimer's disease

 Coordinatore BAR ILAN UNIVERSITY 

 Organization address address: BAR ILAN UNIVERSITY CAMPUS
city: RAMAT GAN
postcode: 52900

contact info
Titolo: Mrs.
Nome: Estelle
Cognome: Waise
Email: send email
Telefono: +972 3 531 7439
Fax: 97236353277

 Nazionalità Coordinatore Israel [IL]
 Totale costo 100˙000 €
 EC contributo 100˙000 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2012-CIG
 Funding Scheme MC-CIG
 Anno di inizio 2012
 Periodo (anno-mese-giorno) 2012-08-01   -   2016-07-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    BAR ILAN UNIVERSITY

 Organization address address: BAR ILAN UNIVERSITY CAMPUS
city: RAMAT GAN
postcode: 52900

contact info
Titolo: Mrs.
Nome: Estelle
Cognome: Waise
Email: send email
Telefono: +972 3 531 7439
Fax: 97236353277

IL (RAMAT GAN) coordinator 100˙000.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

memory    software    decline    binding    acetylcholine    alzheimer    beta    achr    laboratory    disease    cognition    drug    drugs    prevent    promising   

 Obiettivo del progetto (Objective)

'Alzheimer’s disease is a neurodegenerative disease characterized by the accumulation of proteins and protein fragments in the brain, progressive neuronal loss, inflammation, and the gradual and inevitable decline of memory and cognition. Decline of memory and cognition is coupled with binding of β amyloid peptides (Aβ) and their derived diffusible ligands (ADDL) to the nicotinic acetylcholine receptor (AChR). To prevent this binding and improve cognition, we are designing, synthesizing, and testing new drugs that are capable of disrupting the calamitous interactions of Aβ with AChR, dull it’s anesthesia like effect, and prevent neurodegeneration. For drug design, we use proprietary software based on normal mode dynamics developed in our laboratory. These software have shown promising results with 98% accuracy in predicting ligand binding sites and drug screening. For chemical synthesis, we use our highly experienced chemistry laboratory. In the past, we synthesized complex molecules and drugs with high yields. Preliminary results of our drugs are promising in that they bind AChR without interfering with acetylcholine binding. These Aβ like drugs open a new window of opportunity for the treatment and prevention of Alzheimer's disease.'

Altri progetti dello stesso programma (FP7-PEOPLE)

COSMICMAG (2014)

Evaluation of the Uncertainties of the Galactic Magnetic Field to Elucidate the Origin of Ultra-High Energy Cosmic Rays

Read More  

PEP-REP-2 (2010)

In vitro replication of Pepino mosaic virusand characterization of replication essential host (tomato) factors

Read More  

MURF AND HYPERTROPHY (2010)

Regulation and function of the E3 ubiquitin ligases Muscle RING finger 1 and 3 in cardiac hypertrophy

Read More